1-octyl-3-methylimidazolium brimide

We are 1-octyl-3-methylimidazolium brimide CAS:61545-99-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


English Name: 1-octyl-3-methylimidazolium brimide
Synonyms:1-octyl-3-methylimidazolium brimide
Molecular Formula: C12H23BrN2
Molecular Weight: 275.23
CAS No.: 61545-99-1
Purity: 99%
 
Technical Information

Appearance: colorless to slight-yellow liquid	Purity: 99%
NMR: Passed	null
Solubility: dichloromethane, acetone	Insolubility: water, ether,
Impurity content: (1) Methylimidazole content: < 1000 ppm; (2)  Water content: < 1000 ppm

 
Physics-Chemistry Properties

Melting point:	Decomposition temperature:
Conductivity:	Electrochemical window:
Viscosity:	Density:

 
Our company has been engaged in the R&D, production of ionic liquids and related technologies for more than ten years. Since 2007, our company has supplied ionic liquid reagents to customers, and can provide customers with ionic liquid products from grams to hundreds of tons. The main product series are: Imidazolium ionic liquids, single-substituted Im ionic liquids, Disubstituted Im ionic liquids, Tri-Substituted Im ionic liquids, Pyrilidinium ionic liquids, Ammonium ionic liquids, Phosphonium ionic liquids, Pyrrolidinium ionic liquids, Piperidinium ionic liquids, Functionized ionic liquids, Vinyl-Based ionic liquids, Hydroxyl-Based ionic liquids, Ether-Based ionic liquids, Ester-Based ionic liquids, Carboxyl-Based ionic liquids, Nitrile-Based ionic liquids, Amido-Based ionic liquids, SulfoAcid-Based ionic liquids, Benzyl-Based ionic liquids, Guanidine-Based ionic liquids, Oxonium salts



Related News: The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.N-bencil-6- (4-fenilbutoxi) hexan-1-amina CAS:97664-55-6 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.3,4-dihidro-7- (4-bromobutoxi) -2 (1H) -quinolinona CAS:129722-34-5 Profitability continued to improve. The company’s comprehensive gross profit margin for the first three quarters was 36.06%, a year-on-year increase of 3.44 percentage points. Since this year, the company’s profitability has remained at a relatively high level. On the one hand, due to the decline in the trading business with lower profitability, the proportion has declined.6-cloropurina-9-ribósido CAS:2004-06-0 By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant’s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed.ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.